The inaugural summit under its new name builds on two previous editions of Abu Dhabi Global Health Week, with new agreements targeting clinical research, preventive medicine and specialised care
Abu Dhabi has strengthened its international healthcare partnerships through a series of agreements announced at the Abu Dhabi Future Health Summit, held from 20 to 22 October 2026 at the ADNEC Centre. Convened by the Department of Health – Abu Dhabi, the three-day gathering brought together healthcare executives, researchers, technology companies and policymakers to explore how medical innovation can improve disease prevention, diagnosis and treatment.
Under the theme To Sense is to Predict, the summit focused on the growing role of artificial intelligence, genomics, advanced diagnostics and health data in identifying medical risks before diseases progress. The programme covered precision medicine, digital healthcare, health system resilience and investment in life sciences. Organisers had anticipated participation from 100 countries and more than 175 exhibitors, reflecting the event's international ambitions.
The 2026 summit also marked a new stage in an established annual healthcare gathering. Abu Dhabi Global Healthcare Week was first held in May 2024, followed by a second edition in April 2025. The event was subsequently incorporated into Future Health, a year-round initiative launched in 2025 to support international healthcare collaboration. The October 2026 summit was therefore the first under the new name, but the third annual gathering in the event's broader history.
International agreements target medical innovation
Among the most significant announcements was an agreement involving the Department of Health – Abu Dhabi, Cleveland Clinic Abu Dhabi and pharmaceutical company AstraZeneca.
The partners intend to explore opportunities for conducting up to 30 clinical trials by 2030, with a potential investment value estimated at USD 50 million. The programme focuses on cardiovascular, renal and metabolic diseases, with the first six studies targeted to begin before the end of 2026.
The figures represent proposed research activity and potential investment rather than completed studies or committed expenditure.
Abu Dhabi also signed an agreement with Isomorphic Labs to explore artificial intelligence applications in drug discovery. The collaboration envisages a 24-month preclinical research roadmap, using Abu Dhabi's research infrastructure to investigate selected projects.
Another agreement with wearable technology company WHOOP focuses on research into preventive health, including cardiovascular and metabolic risk assessment. Such partnerships reflect Abu Dhabi's strategy of linking clinical research with digital technologies and population health programmes.
The initiatives could strengthen the emirate's attractiveness to international pharmaceutical companies, researchers and specialist healthcare providers. Their contribution to patient care, however, will depend on subsequent research results, regulatory approvals and clinical implementation.
Advanced therapies could reduce overseas treatment
A separate agreement between the Abu Dhabi Stem Cells Centre (ADSCC) and Miltenyi aims to expand the development and local manufacturing of CAR-T cell therapies in the UAE.
CAR-T therapy involves modifying a patient's immune cells to recognise specific targets. The approach is established for certain blood cancers, while applications in autoimmune and other diseases remain subject to ongoing clinical research.
Under the agreement, ADSCC will contribute its existing cell-processing and manufacturing infrastructure, while Miltenyi will provide scientific and technical expertise. The partners also intend to explore applications beyond oncology.
The collaboration has particular significance for international patient mobility. By developing local access to highly specialised cellular treatments, Abu Dhabi hopes to reduce the need for eligible patients to travel abroad. Whether the programme will eventually attract patients from neighbouring countries remains to be established.
From annual conference to year-round platform
The Future Health Summit builds on Abu Dhabi's earlier efforts to establish an international forum for healthcare innovation.
The inaugural Abu Dhabi Global Healthcare Week took place from 13 to 15 May 2024. Its second edition, held from 15 to 17 April 2025, attracted 14,290 visitors, 1,295 delegates and 140 exhibitors from 95 countries, according to the Department of Health – Abu Dhabi. The 2025 programme also facilitated 33 strategic agreements involving healthcare, research and technology organisations.
Following the launch of the Future Health initiative in 2025, the annual summit became part of a broader programme of international dialogues, research activities and innovation partnerships.
The organisers describe the summit as an annual flagship event, although no confirmed dates for the 2027 edition have yet been published.
For Abu Dhabi, the agreements announced in October 2026 illustrate a strategy extending beyond conventional medical tourism. The emirate is seeking to combine specialist clinical services, local treatment capacity, international research partnerships and pharmaceutical innovation within a single healthcare ecosystem.
For regional patients, the most tangible potential benefit is improved access to complex medical services closer to home. For international healthcare organisations, Abu Dhabi is developing opportunities for clinical cooperation, research and investment. The extent to which these initiatives translate into additional treatment capacity and cross-border patient flows will become clearer as the announced projects progress.
Image Credit: AI generated illustration
